Australian Technology Innovation Fund Limited

1. Australian Technology Innovation Fund Limited Prospectus presentation Your entry into the lucrative biotechmarket

2. The biotech market • Biotechnology is a highly specialised sector offering excellent investment opportunities to those able to identify projects with global commercialisation potential. • ATIF identifies and develops biotechnology projects of the highest potential in Australia and offshore. This is your opportunity to own a share of the lucrative biotech market.

3. The biotech market • Traditionally, there is a lack of suitable entities in the biotech market with: • The complex skills required to target appropriate biotechnology investments • The ability to cost-effectively manage the risk profile of a specialised biotechnology portfolio. ATIF has the experienced management and complex skills required for success in this field.

4. About ATIF • ATIF holds an attractive and diverse asset base through its interests in three Australian biotechnology companies: • CBio Limited (16.37%) • Psiron Limited (15.93%) • Analytica Limited (14.71%) ATIF provides assistance to these companies to achieve their commercial objectives.

5. About ATIF • Directors • Dr Wolf Hanisch – more than 20 years experience in the biotech industry, including a $45 million IPO for Idec Pharmaceuticals. • Mr Stephen Jones – corporate recovery and turnaround specialist. Former member of Qld Govt’s Queensland Innovation Council.

6. About ATIF • Directors cont… • Dr Michael Monsour – medical practitioner with business interests in QLD medical centres. ATIF has specialist expertise in biotechnology and capital financing sectors – a key ATIF advantage.

7. About ATIF • ATIF’s Board and Management have high-level scientific and financial experience and are intending ATIF to become Australia’s leading diversified biotechnology company. • ATIF intends to retain its focus on biotechnology investment, and has formulated the following business plan.

8. ATIF Business Plan • Fulfil own working capital needs from revenues raised through specialist corporate advisory to biotech sector. • Effective ongoing management of existing interests. • Assisting ATIF investments in achieving product development and funding outcomes.

9. ATIF Business Plan • Identifying new investment opportunities and industry alliances both in Australia and overseas. • Integrating acquisitions and developing well-timed “spin off” IPO opportunities. The ATIF Business Plan gives a clear path for success in the biotech sector.

10. ATIF’s Investments • ATIF has stringent criteria used in selecting current and future investments: • Product-focussed investment approach • Risk management • Technical competence and skilled hands-on management • IP protection and product-base diversification

11. ATIF’s Investments • ATIF’s investments are diversified among a variety of complementary biotech areas: • CBio Ltd • Immune System modulation • Psiron Ltd • Anti-inflammation, Anti-cancer • Analytica Ltd • Diagnostics

12. CBio Ltd • Unlisted Australian Public Company who owns patent for hormone Early Pregnancy Factor (EPF). • EPF has patented applications in: • auto-immune disease market (MS and R. Arthritis) • organ rejection • burns treatment • cancer (diagnosis and therapy) • being prepared for listing “04-05” on appropriate international exchange.

13. Psiron Ltd • Australian Public Company which listed on ASX. • Operates in biotech/healthcare segment and has investments in • Analytica Ltd. • CBio

14. Psiron Ltd • Therapeutics interests are in anti-cancer and anti-inflammation such as: • SPLA2 anti-inflammation • New generation anti-inflammatory • Psorafin psoriasis • Psiron owns worldwide rights to the patented Sorafin compound (treatment for Psoriasis) under and exclusive license. • Psoriasis is one of the world’s most common skin diseases.

15. Analytica Ltd • Australian public company listed on the ASX. • Diagnostics business with current annual sales revenues of approximately $1.2 million.

16. The ATIF advantage Established to take advantage of value-priced investment opportunities in the biotechnology sector, ATIF offers industry-specific expertise and an established and diverse portfolio of biomedical projects and patents.

17. The ATIF advantage • ATIF has the specialist expertise to surmount traditional biotech investment barriers. • ATIF fills a void in the investment sector.

18. The ATIF share offer • 5 million fully-paid shares in ATIF Ltd are on offer at an issue price of $1.00 each. • Minimum requirement 2000 shares at $1.00 per share, or greater numbers in multiples of 1000 thereafter. • Applications accepted from 23 October 2002 until 20 December 2002.

19. The ATIF share offer • Why Invest in ATIF? • Excellent capital growth opportunities • Exclusive preferential access to additional investment opportunities, including underwriting and sub-underwriting agreements, IPOs and other share issues • The benefit of diversification in the biotechnology sector

20. The ATIF share offer By investing in ATIF, shareholders: • Gain ownership of an excellent capital growth opportunity • Gain access to key “deal maker” positions resulting from ATIF initiatives

21. Your opportunity • This is your opportunity to invest in an attractive and diverse biotechnology asset base, and benefit from: • Diversity through ATIF’s four investments for price of one • Low entry price for new investments • Strong Board and Management team with real experience

22. Your opportunity • Further information for your perusal: • Prospectus for Australian Technology Innovation Fund Limited share offer

23. Your questions answered • If you have any questions or would like a copy of the complete prospectus, contact us at ATIF on: Ph. 07 3371 3000Fax. 07 3371 3011Email. monsour@atif.biz PO BX 3104South Brisbane BCQLD 4101 Australia

24. Your entry into the lucrative biotech market